FRE.DE - Fresenius SE & Co. KGaA

XETRA - XETRA Delayed price. Currency in EUR
69.14
+0.06 (+0.09%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous close69.08
Open69.00
Bid0.00 x 120700
Ask0.00 x 6100
Day's range68.92 - 69.58
52-week range58.96 - 80.07
Volume2,302,905
Avg. volume1,386,128
Market cap38.353B
Beta0.90
PE ratio (TTM)21.26
EPS (TTM)3.25
Earnings date31 Jul 2018
Forward dividend & yield0.75 (1.19%)
Ex-dividend date2018-05-22
1y target estN/A
  • Fresenius CEO defends cancelled Akorn deal
    Reuters2 days ago

    Fresenius CEO defends cancelled Akorn deal

    FRANKFURT/BERLIN (Reuters) - Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion (3.6 billion pounds) takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker. "It was certainly not an easy decision, but ultimately there was only one correct course," CEO Stephan Sturm, a former investment banker and experienced dealmaker, said at Fresenius' annual shareholder meeting in Frankfurt on Friday. Did you really take a close look at Akorn before making your purchase offer?’," he said.

  • EQS Group3 days ago

    Fresenius Medical Care forecasts continued strong growth - Annual General Meeting approves 21st straight dividend increase

    DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): AGM/EGM17.05.2018 / 14:22 The issuer is solely responsible for the content of this announcement.

  • EQS Group9 days ago

    Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Fresenius SE & Co. KGaA11.05.2018 / 14:16 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Notification of Major Holdings1. Details of issuerFresenius SE & Co. KGaAElse-Kröner-Straße 161352 Bad Homburg v.d.H.Germany2. Reason for notificationXAcquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rightsXOther reason:Voluntary group notification with triggered threshold on subsidiary level3. ...

  • EQS Group13 days ago

    Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Fresenius SE & Co. KGaA07.05.2018 / 15:37 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Notification of Major Holdings1. Details of issuerFresenius SE & Co. KGaAElse-Kröner-Straße 161352 Bad Homburg v.d.H.Germany2. Reason for notificationXAcquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason:3. ...

  • EQS Group17 days ago

    Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Fresenius SE & Co. KGaA03.05.2018 / 17:48 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Notification of Major Holdings1. Details of issuerFresenius SE & Co. KGaAElse-Kröner-Straße 161352 Bad Homburg v.d.H.Germany2. Reason for notificationXAcquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason:3. ...

  • Fresenius sees Akorn lawsuit dragging on into 2019
    Reuters17 days ago

    Fresenius sees Akorn lawsuit dragging on into 2019

    German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

  • Reuters17 days ago

    Fresenius sees Akorn lawsuit dragging on into 2019

    German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its cancelled $4.7 billion (3.5 billion pounds) takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

  • Associated Press17 days ago

    Fresenius: 1Q Earnings Snapshot

    The Bad Homburg, Germany-based company said it had net income of 56 cents per share. Earnings, adjusted for non-recurring gains, were 49 cents per share. The dialysis services provider posted revenue of ...

  • Reuters - UK Focus17 days ago

    European shares dip on heavy earnings day as euro rebounds

    European bourses fell in morning trading on Thursday, weighed down by a rebound in the euro and a series of disappointing earning updates including from Smith & Nephew. The pan-European STOXX 600 index ...

  • EQS Group17 days ago

    Fresenius Medical Care remains on track for another record year after solid first quarter 2018

    DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Quarter Results03.05.2018 / 07:00 The issuer is solely responsible for the content of this announcement.

  • Reuters18 days ago

    Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

    WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn slid nearly 15 percent on Wednesday to end at $12.55 per share.

  • Reuters18 days ago

    Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

    WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion (3.5 billion pounds), according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn fell more than 8 percent in early trading Nasdaq on Wednesday to $13.57 per share.

  • Akorn Accused of Sending Phony Data to FDA on Antibiotic
    Bloomberg18 days ago

    Akorn Accused of Sending Phony Data to FDA on Antibiotic

    Akorn Inc. officials allegedly submitted phony data to regulators about an antibiotic drug, prompting Fresenius SE to pull out of a $4.3 billion buyout of the generic drugmaker. An investigation tied to the deal found an Akorn executive “knowingly directed the submission of fraudulent testing data’’ about the company’s azithromycin product to the U.S. Food and Drug Administration in 2012, Fresenius said Wednesday in documents unsealed in Delaware Chancery Court. Akorn has argued Fresenius wrongfully pulled out of the $34-per-share deal because of buyer’s remorse -- not any findings that its officials had misled regulators about product-development practices.

  • EQS Group20 days ago

    Fresenius SE & Co. KGaA: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Fresenius SE & Co. KGaA / Total Voting Rights Announcement30.04.2018 / 19:24 Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publication of total number of voting rights1. Details of issuerFresenius SE & Co. KGaAElse-Kröner-Straße 161352 Bad Homburg v.d.H.Germany2. Type of capital measure Type of capital measureDate of status / date of effectXConditional capital increase (Sec. 41 para. 2 WpHG)30.04.2018 Other capital measure (Sec. 41 para. 1 WpHG)3. ...

  • EQS Group25 days ago

    Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Fresenius SE & Co. KGaA25.04.2018 / 17:40 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Notification of Major Holdings1. Details of issuerFresenius SE & Co. KGaAElse-Kröner-Straße 161352 Bad Homburg v.d.H.Germany2. Reason for notificationXAcquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rightsXOther reason:Voluntary group notification with triggered threshold on subsidiary level3. ...

  • Akorn Shares Crash After Fresenius Walks Away From Merger Deal
    Investor's Business Daily27 days ago

    Akorn Shares Crash After Fresenius Walks Away From Merger Deal

    Akorn shares lost more than a third of their value early Monday after Fresenius walked away from a pending $4.3 billion acquisition.

  • A Fallen Akorn Is Too Expensive for Fresenius
    Bloomberg27 days ago

    A Fallen Akorn Is Too Expensive for Fresenius

    German medical-equipment maker Fresenius SE on Sunday announced it was terminating its $4.3 billion merger agreement with generic drugmaker Akorn Inc. Fresenius said in February it was looking into possible breaches of FDA drug data standards by Akorn, and the results of that probe led it to Sunday's decision. If Fresenius found something in its investigation bad enough to justify breaking off the deal, then it's certainly making the right move. It was a strategic fit for Fresenius and looked relatively cheap after a sales slowdown had hit Akorn's share price.

  • Reuters27 days ago

    Jilted Akorn sues Fresenius over deal termination

    U.S. generic drugmaker Akorn (AKRX.O) is taking former suitor Fresenius (FREG.DE) to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.

  • EQS Group27 days ago

    Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius

    Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions/Legal MatterFresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius23-Apr-2018 / 16:53 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

  • Jilted Akorn sues Fresenius over deal termination
    Business Insider UK27 days ago

    Jilted Akorn sues Fresenius over deal termination

    U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.

  • Jilted Akorn sues Fresenius over deal termination
    Business Insider UK27 days ago

    Jilted Akorn sues Fresenius over deal termination

    U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.

  • MarketWatch27 days ago

    Akorn files complaint against Fresenius for ending merger deal

    Akorn Inc. said Monday it has filed a complaint against Fresenius SE & Co. in a Delaware court, asking that Germany-based Fresenius be required to fulfill its obligations to complete its buyout agreement. Earlier, Fresenius said it was ending the deal to buy the generic drug maker, following an investigation into possible violations of Food and Drug Administration data-integrity requirements, which Akorn responded by saying it "categorically" disagreed with the decision. In the filing with the Delaware court, Akorn said the attempt to end the merger is a breach of the agreement without merit.

  • MarketWatch27 days ago

    Akorn's stock plunged toward 5-year low after Fresenius terminates merger deal

    Shares of Akorn Inc. plunged 36% toward a 5-year low in premarket trade Monday, after Germany-based healthcare company Fresenius SE & Co. said it terminated the deal to buy the generic drug maker. Fresenius ...

  • Associated Press27 days ago

    Germany's Fresenius, US-based Akorn at odds over merger deal

    BERLIN (AP) — Germany's Fresenius and U.S.-based pharmaceutical manufacturer Akorn Inc. are at odds over the German company's decision to terminate a more than $4.3 billion takeover agreement, citing alleged breaches of data integrity requirements.

  • Fresenius Abandons $4.3 Billion Akorn Takeover Bid
    Bloomberg Video27 days ago

    Fresenius Abandons $4.3 Billion Akorn Takeover Bid

    Apr.23 -- Bloomberg’s Ed Hammond discusses a takeover deal that didn’t materialize. He speaks with Alix Steel and David Westin on "Bloomberg Daybreak: Americas."

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes